O-serogroup, virulence factors and phylogenetic group of uropathogenic
O-serogroup | Year | Virulence factors | Phylogenetic group | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A | B1 | B2 | D | Total | |||||||||
O1 | 1989 | 6 (100%) | 2 (33.3%) | 2 (33.3%) | 5 (83.3%) | - | - | - | - | - | 6 | 6 (4.9%) | |
2010-2014 | 36 (90%) | 4 (10%) | 12 (57.5%) | 3 (7.5%) | 8 (20%) | 4 (10%) | - | - | 20 | 20 | 40 (7.2%) | ||
O2 | 1989 | 3 (100%) | 3 (100%) | 1 (33.3%) | 2 (66.7%) | 3 (100%) | 2 (66.7%) | - | - | 3 | - | 3 (2.4%) | |
2010-2014 | 68 (98.6%) | 19 (27.5%) | 63 (91.3%) | 8 (11.6%) | 24 (34.8%) | 3 (4.3%) | - | - | 65 | 4 | 69 (12.4%) | ||
O4 | 1989 | 2 (100%) | 2 (100%) | 2 (100%) | 2 (100%) | 2 (100%) | 1 (57.1%) | 1 | - | 2 | - | 3 (2.4%) | |
2010-2014 | 9 (100%) | 5 (55.6%) | 4 (44.4%) | 4 (44.4%) | 5 (55.6%) | 3 (33.3%) | 1 | 2 | 6 | - | 9 (1.6%) | ||
O6 | 1989 | 11 (78.6%) | 8 (57.1%) | 8 (57.1%) | 9 (64.3%) | 8 (57.1%) | 8 (57.1%) | 5 | - | 9 | - | 14 (11.4%) | |
2010-2014 | 43 (100%) | 30 (69.8%) | 27 (62.8%) | 26 (60.5%) | 30 (69.8%) | 25 (58.1%) | 2 | 2 | 30 | 9 | 43 (7.7%) | ||
O7 | 1989 | 1 (100%) | - | - | - | - | - | - | - | - | 1 | 1 (0.8%) | |
2010-2014 | 3 (60%) | 1 (20%) | 1 (20%) | 1 (20%) | - | - | 2 | - | 1 | 2 | 5 (0.9%) | ||
O8 | 1989 | 6 (66.7%) | - | 1 (11.1%) | - | - | - | 2 | 2 | 1 | 4 | 9 (7.3%) | |
2010-2014 | 17 (85%) | 3 (15%) | 1 (5%) | 2 (10%) | 2 (10%) | - | 5 | 6 | 7 | 2 | 20 (3.6%) | ||
O15 | 1989 | - | - | - | - | - | - | - | - | - | - | - | |
2010-2014 | 17 (89.5%) | 1 (5.3%) | 9 (47.4%) | 3 (15.8%) | 8 (42.1%) | 1 (5.3%) | 4 | - | 2 | 13 | 19 (3.4%) | ||
O16 | 1989 | - | - | - | - | - | - | - | - | - | - | - | |
2010-2014 | 14 (100%) | - | 4 (28.6%) | - | - | 1 (7.1%) | 2 | - | 9 | 3 | 14 (2.5%) | ||
O18 | 1989 | - | - | - | - | - | - | - | - | - | - | - | |
2010-2014 | 15 (100%) | 2 (13.3%) | 3 (20%) | 6 (40%) | 4 (26.7%) | 3 (20%) | 3 | 1 | 6 | 5 | 15 (2.7%) | ||
O21 | 1989 | 4 (100%) | - | 4 (100%) | 3 (75.0%) | - | 4 (100%) | - | - | 4 | - | 4 (3.3%) | |
2010-2014 | 3 (100%) | 1 (33.3%) | 1 (33.3%) | - | 1 (33.3%) | 1 (33.3%) | 1 | 1 | - | 1 | 3 (0.5%) | ||
O22 | 1989 | - | - | - | - | - | - | - | - | - | - | - | |
2010-2014 | 5 (100%) | - | 1 (20%) | 2 (40%) | - | - | - | - | 2 | 3 | 5 (0.9%) | ||
O25 | 1989 | 12 (100%) | - | - | 2 (16.7%) | - | - | - | - | 9 | 3 | 12 (9.8%) | |
2010-2014 | 110 (94%) | 12 (10.3%) | 37 (31.6%) | 10 (8.5%) | 24 (20.5%) | 17 (14.5%) | 7 | 5 | 96 | 9 | 117 (21.0%) | ||
O75 | 1989 | 12 (100%) | 1 (8.3%) | 6 (50.0%) | 8 (66.7%) | 1 (8.3%) | 2 (16.7%) | 1 | 1 | 8 | 2 | 12 (9.8%) | |
2010-2014 | 57 (95%) | 1 (1.7%) | 2 (3.3%) | 56 (93.3%) | 10 (16.7%) | - | 1 | - | 57 | 2 | 60 (10.8%) | ||
O83 | 1989 | 4 (100%) | - | - | 2 (50.0%) | - | - | - | - | 4 | - | 4 (3.3%) | |
2010-2014 | 2 (66.7%) | 1 (33.3%) | 1 (33.3%) | 1 (33.3%) | - | - | 1 | - | 2 | - | 3 (0.5%) | ||
Other serogroup | 1989 | 42 (76.4%) | - | 2 (3.6%) | 10 (18.2%) | - | 2 (3.6%) | 21 | 8 | 7 | 19 | 55 (44.7%) | |
2010-2014 | 118 (86.8%) | 19 (14%) | 31 (22.8%) | 30 (22.1%) | 30 (22.1%) | 10 (7.4%) | 27 | 13 | 42 | 54 | 136 (24.4%) |